

Call for Applications: Clinical Research Grant for Oncology and Hematology 2026

The **Tumor Center of the University Hospital Basel (USB)** invites applications for the Clinical Research Grant for Oncology and Hematology, primarily supporting early-career clinician-scientists in conducting clinical research projects relevant to cancer care.

Funding	Project Duration
CHF 27,500	12–24 months

Scope

The grant supports clinical research with direct relevance to oncology, hematology, surgical oncology, imaging in cancer, and diagnostics in cancer. Applications for ongoing projects are also welcome. Interdisciplinary proposals combining expertise from multiple fields are particularly encouraged. The grant is open to all specialties, provided the project contributes to improving cancer care.

Eligibility

- Clinically active early-career researchers (within 10 years of MD, PhD, or equivalent degree)
- Current affiliation with the University Hospital Basel or associated academic institutions
- Funding is primarily intended to provide protected research time
- Joint applications from two early-career researchers are welcome (funding will be shared)

Application Requirements

Applications must be submitted in **English** and include:

- **Curriculum Vitae** (max. 1 page)
- **Project Description** (max. 3 pages), structured as follows:
 - Background
 - Patients and Methods
 - Results (if applicable)
 - Clinical Impact

Review Criteria

- Clinical relevance and potential impact (40%)
- Scientific quality and methodology (35%)
- Innovation (15%)
- Environment and resources (10%)

Timeline

- **Application deadline:** 29 May 2026
- **Review period:** June – July 2026
- **Award announcement:** August/September 2026

Submission

Please send your application as a single PDF to: **USB Tumorzentrum** – tumorzentrum@usb.ch

The Clinical Research Grant is funded through a multi-pharma sponsorship model, ensuring independence and transparency. The selection of the funded project is made solely by the independent review committee based on scientific criteria. Supported by: Be One Medicine, BMS, Daiichi Sankyo, Incyte, Roche, Servier.

